| Most common adverse reactions (≥2%, pooled safety data across PRIME and PRIME2)1 |
||
| ADVERSE REACTION (AR) |
DUPIXENT 300 mg Q2W (n=152) |
PLACEBO (n=157) |
|---|---|---|
| Nasopharyngitisa | 5% | 2% |
| Conjunctivitisb | 4% | 1% |
| Herpes Infectionc | 3% | 0% |
| Dizzinessd | 3% | 1% |
| Myalgiae | 3% | 1% |
| Diarrhea | 3% | 1% |
aNasopharyngitis includes pharyngitis.
bConjunctivitis includes conjunctivitis and allergic conjunctivitis.
cHerpes infection includes oral herpes, genital herpes simplex, herpes zoster, and ophthalmic herpes zoster.
dDizziness includes dizziness postural, vertigo, and vertigo positional.
eMyalgia includes musculoskeletal pain and musculoskeletal chest pain.
DISCONTINUATION DUE TO ADVERSE EVENTS: 0% with DUPIXENT vs 3% with placebo- Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment
Important considerations
NO BOXED WARNING1
Select important safety
information
warnings and precautions
- Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT
NOT METABOLIZED THROUGH THE LIVER
OR EXCRETED THROUGH THE KIDNEYS1
- No known drug-to-drug interactions
Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.
Other attributes
DUPIXENT IS NOT AN
IMMUNOSUPPRESSANT1
NO REQUIREMENT FOR INITIAL LAB TESTING OR ONGOING LAB MONITORING, according to the Prescribing Information1
Q2W, once every 2 weeks.